Immune Diagnostics Kypha offers real-time, point-of-care measurement of immune elements such as complement proteins, cytokines, and chemokines, presenting a compelling value proposition for hospitals, clinics, and research centers seeking rapid immune-status insights to inform therapeutic decisions.

Multiplex Capability With both single analyte (CompAct) and multiplex (RapiPlex) options that deliver results within minutes, Kypha can target customers needing scalable panels for precision monitoring of immune status and inflammatory conditions.

Strategic Growth Recent acquisition of Biosensia and subsequent funding indicate a growth-focused trajectory, suggesting selling opportunities to expand Kypha’s manufacturing, deployment, and product commercialization network.

Financial Footing Revenue in the low-to-mid single-digit millions with total funding of around $24M positions Kypha as an emerging diagnostics player with appetite for channel partnerships, OEM collaborations, and co-development agreements.

Industry Fit Target markets include immune-related conditions and precision monitoring needs in research and clinical settings, offering potential partnerships with hospitals, biotechs, CROs, and contract development/manufacturing organizations seeking real-time immune analytics.